1. Home
  2. NA vs BMEA Comparison

NA vs BMEA Comparison

Compare NA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NA

Nano Labs Ltd

HOLD

Current Price

$3.01

Market Cap

98.5M

Sector

Technology

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.44

Market Cap

96.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NA
BMEA
Founded
2019
2017
Country
China
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
98.5M
96.9M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
NA
BMEA
Price
$3.01
$1.44
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.71
AVG Volume (30 Days)
181.7K
1.7M
Earning Date
08-15-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,369,693.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.75
$0.87
52 Week High
$31.48
$6.30

Technical Indicators

Market Signals
Indicator
NA
BMEA
Relative Strength Index (RSI) 29.42 56.50
Support Level $2.75 $0.95
Resistance Level $3.25 $1.56
Average True Range (ATR) 0.29 0.13
MACD -0.09 0.07
Stochastic Oscillator 14.37 76.19

Price Performance

Historical Comparison
NA
BMEA

About NA Nano Labs Ltd

Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: